Информация о подписке на архивные копии (Print ISSN 1606–8181 + CD-Rom ISSN 1999–7337):
СЧЕТ НА ПОДПИСКУ НА 2 ПОЛУГОДИЕ 2010 г.
Пресс-релизы
Пресс-релиз: Определение показателей научного рейтинга |
|
| В последнее время уделяется всё большее внимание научным рейтингам исследователей, научных коллективов и организаций. Общепринятыми показателями научного рейтинга ученых являются: количество статей, опубликованных в научных журналах и других изданиях, включенных в базы данных Web of Science и Scopus; цитируемость этих публикаций; показатели импакт-фактора научных журналов, в которых были опубликованы работы исследователей. 13.08.2010 |
Далее... |
Научная жизнь: Report Urges More Curbs on Medical Ghostwriting |
|
| A new Congressional report calls on medical journals, and even the to take additional measures to ensure the integrity of the scientific articles many doctors rely on to make treatment decisions for their patients. 01.07.2010 |
Далее... |
Научная жизнь: 15th International "Stress and Behavior" Neuroscience and Biopsychiatry Conference |
|
| An annual international event gathering scientists and psychiatrists from around the world to share an interest in stress-evoked brain disorders in both humans and animals. Since 1997, it has been co-organized by the Centre for Physiology and Biochemical Research (CPBR), the Russian Society for Bio-psychiatry (RSBP), the Ukrainian Society for Biological Psychiatry (USBP) and the Institute of Experimental Medicine (IEM). 28.06.2010 |
Далее... |
Пресс-релиз: AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214 as an Adjunct Treatment for Major Depressive Disorder |
|
| AstraZeneca and Targacept, Inc., today announced the enrolment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker. The Phase 3 program, referred to as the Renaissance Program, is designed to support the planned second half of 2012 filing of a new drug application with the U.S. Food and Drug Administration for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norephinephrine reuptake inhibitor (SNRI). A Marketing Authorisation Application in Europe is planned for 2014. 27.06.2010 |
Далее... |
| Другие объявления... |